Global Custom Market Research Reports Provider Company

phone

Aimmune Therapeutics Inc (AIMT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 34
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

Aimmune Therapeutics Inc (Aimmune), formerly Allergen Research Corp is a clinical-stage biopharmaceutical company that develops proprietary product candidates for the treatment of peanut and other food allergies. The companys lead product candidate AR101 is used to treat the peanut allergy. Its pipeline program portfolio uses characterized oral desensitization immunotherapy (CODIT), a proprietary approach to oral immunotherapy. Aimmune discovers, develops and commercializes therapies related to food allergy. The company conducts academic research in partnership with various universities and other companies to develop novel product candidates. The company operates in the US and the UK. Aimmune is headquartered in Brisbane, California, the US.

Aimmune Therapeutics Inc (AIMT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 4
List of Figures 4
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Allergen Research Raises USD80 Million in Series B Financing 10
Allergen Research Raises US$17 Million In Series A Financing 12
Partnerships 13
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 13
Aimmune Therapeutics Enters into Agreement with Nestle Health Science 14
Equity Offering 15
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 15
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 17
Aimmune Therapeutics Raises USD184 Million in IPO 18
Aimmune Therapeutics Inc - Key Competitors 19
Aimmune Therapeutics Inc - Key Employees 20
Aimmune Therapeutics Inc - Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Strategy And Business Planning 22
Jun 07, 2017: CoreRx and Aimmune Therapeutics Joint Expansion to Create Pharmaceutical Jobs and Increase the Base of Scientific Capabilities in the Tampa Bay Area 22
Financial Announcements 23
Mar 12, 2018: Aimmune Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 23
Nov 06, 2017: Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018 25
Aug 08, 2017: Aimmune Therapeutics Announces Second Quarter 2017 Financial Results 27
May 08, 2017: Aimmune Therapeutics Announces First Quarter 2017 Financial Results 29
Mar 15, 2017: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results 30
Corporate Communications 32
Feb 14, 2018: Aimmune Therapeutics Names George du Toit and Wayne Shreffler to Scientific Advisory Board 32
Apr 13, 2017: Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List Of Tables

List of Tables
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Allergen Research Raises USD80 Million in Series B Financing 10
Allergen Research Raises US$17 Million In Series A Financing 12
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 13
Aimmune Therapeutics Enters into Agreement with Nestle Health Science 14
Aimmune Therapeutics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD202.4 Million 15
Aimmune Therapeutics Raises USD145 Million in Private Placement of Shares 17
Aimmune Therapeutics Raises USD184 Million in IPO 18
Aimmune Therapeutics Inc, Key Competitors 19
Aimmune Therapeutics Inc, Key Employees 20
Aimmune Therapeutics Inc, Other Locations 21

List Of Figures

List of Figures
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aimmune Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aimmune Therapeutics Inc (Aimmune), formerly Allergen Research Corp is a clinical-stage biopharmaceutical company that develops proprietary product candidates for the treatment of peanut and other food allergies. The companys lead

View Report

Aimmune Therapeutics Inc (Aimmune), formerly Allergen Research Corp is a clinical-stage biopharmaceutical company that develops proprietary product candidates for the treatment of peanut and other food allergies. The companys lead

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports